Even though the rate of brain involvement at initial diagnosis of ALK+ lung cancers is similar to that of other NSCLC, namely approximately 25% [26,27], brain control is especially important for ALK+ patients, because they are generally younger and have a longer life expectancy, wherefore quality of life matters more. This evidence concerns the gene ALK and non-small cell lung carcinoma.